[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aston University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":116},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,69,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100634135","phase-3-the-effect-of-myopia-control-contact-lenses-in-new-zealand-chinese-children-100634135",false,"NCT07535749","The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children","Inclusion Criteria:\n\n* Spherical refractive error between -1.00D and -4.50D\n* Astigmatism of ≤1.00D\n* No history of orthokeratology or atropine use\n* No ocular diseases or surgical history\n\nExclusion Criteria:\n\no No ocular diseases or surgical history","ALL","7 Years","11 Years",{"count":19,"type":20},66,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The study will employ a randomized, controlled, investigator-masked paired-eye comparison design to evaluate the effects of two myopia-control contact lenses-MiSight 1 Day and Abiliti 1-Day-in New Zealand Chinese children.\n\nThe study duration will be 6 months, with assessments conducted at baseline, 2 weeks, 3 months, and 6 months.\n\nThe clinical research will be conducted at the Auckland Myopia Clinic (New Zealand) and will follow a standard clinical routine for children with early myopia, the only difference being the randomizing of the MiSight and Abiliti contact lenses between the two eyes of the participants.",[26],"Myopia Progression",[28,29],"myopia control","contact lenses","RECRUITING","2026-04-10",{"date":33,"type":34},"2026-04-17","ACTUAL",{"date":36,"type":34},"2026-03-21",{"date":38,"type":20},"2026-12-30",{"name":40,"class":41},"Aston University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100563383","impact-of-tixel-treatment-on-symptoms-and-signs-in-patients-with-dry-eye-disease-100563383","NCT06615453","Impact of Tixel Treatment on Symptoms and Signs in Patients With Dry Eye Disease","A Prospective Study Assessing the Impact of Tixel Treatment of Peri Orbital Wrinkles on Symptoms and Signs in Patients With Dry Eye Disease","TIXEL-DED","Inclusion Criteria:\n\n1. Mild to Moderate Periorbital wrinkles\n2. OSDI score of at least 23\n3. Noninvasive Tear film break up time (NIBUT) ≤ 10 seconds\n4. No other eye or skin or immune problems\n5. Willing and able to provide written informed consent.\n6. Willing to participate in all study activities and instructions.\n\nExclusion Criteria:\n\n1. Pregnancy and\u002For breastfeeding\n2. Lesions in the periorbital area\n3. Acute severe blepharitis\n4. Acute conjunctivitis\n5. Use of eye drops within 2 hours before examination\n6. Other concomitant anterior eye disease\n7. Has undergone outdoors\u002Fsunbed tanning during the last 4 weeks\n8. Is unwilling to follow the Tixel aftercare instructions after each of the three Tixel treatments.\n9. Active Herpes Simplex or tendency for Herpes Simplex in the periorbital area (meaning the subject has had the condition previously).\n10. Current skin cancer, malignant sites and\u002For advanced premalignant lesions or moles in the treatment area.\n11. An impaired immune system condition or use of immunosuppressive medication.\n12. Collagen disorders, keloid formation and\u002For abnormal wound healing.\n13. Previous invasive\u002Fablative procedures in the areas to be treated within 3 months prior to initial treatment or plans for such treatment during the course of the Tixel2 device treatment, or before complete healing of such treatments has occurred.\n14. Any patient who takes or has taken any medications (including via topical application), herbal treatment (oral or topic), food supplements or vitamins, which may cause fragile skin or impaired skin healing during the last 3 months.\n15. Any patient who has used oral Isotretinoin (Accutane® or Roaccutan®) within 3 months prior to treatment or less.\n16. Any patient who has a history of bleeding coagulopathies or use of anticoagulants.\n17. Any patient who has tattoos or permanent makeup in the treated area.\n18. Any patient who has burned skin, blistered skin, irritated skin, or sensitive skin in any of the areas to be treated.\n19. Any patient who underwent thread lifting of the area to be treated in the last 3 months.","18 Years",{"count":53,"type":20},36,[55],"NA","This study will examine how a standard Tixel treatment versus a sham treatment for eye wrinkles affects the symptoms and signs of Dry Eye Disease.",[58],"Dry Eye Disease (DED)",[60],"Dry eye disese, Tixel treatment","2026-01-23",{"date":63,"type":34},"2026-01-26",{"date":65,"type":34},"2024-09-17",{"date":67,"type":20},"2026-07-31",{"name":40,"class":41},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":92},"100544623","photobiomodulation-with-red-vs-blue-light-rebel-100544623","NCT06371300","Photobiomodulation With REd vs BluE Light (REBEL)","Photobiomodulation of the Ocular Surface and Eyelids With Different Wavelengths: REd vs BluE Light (REBEL)","Inclusion Criteria:\n\n* Individuals with dry eye disease symptoms (Ocular Surface Disease Index questionnaire (OSDI) score ≥ 13 or Dry Eye Questionnaire (DEQ5) score \\> 6) and signs (tear film instability measured with non-invasive tear break-up time \\\u003C 10 s or ocular surface damage measured using special dyes placed on the front surface of the eyes that temporarily stains any aggravated or damaged cells: \\> 5 corneal spots, \\> 9 conjunctival spots or lid margin staining ≥ 2mm in length and ≥ 25% in width)\n* Individuals need to also have Meibomian gland dysfunction. The diagnosis of Meibomian gland dysfunction depends on how many of 5 glands in the central lower eyelid can express oil, and the quality of the oil. A diagnosis is made if there is decreased expressibility (grade 1-3 on the Pflugfelder scale) and reduced quality of oil (grade 1-3 on Bron scale). Any presence of gland blockage and\u002For loss of oil glands grade 1 to grade 4 of either eyelid \\[Pult and Reide-Pult, 2013\\]) will also justify a diagnosis of Meibomian gland dysfunction.\n* Individuals will also need to have ocular demodicosis, diagnosed by clinical observation on slit lamp biomicroscope based on signs including collarettes around the base of lashes, visible Demodex tails, or excessive pouting of lash follicles in those with good lid hygiene where Demodex was confirmed by secondary means such as visible Demodex tails.\n* Age ≥ 18 years, male or female\n* Able to provide written consent in English\n* Able to attend a total of 4 visits: 3 treatment visits and followed up for 1 month after final treatment\n\nExclusion Criteria:\n\n* Pregnancy\n* Ocular light-based therapies including intense pulsed light (IPL) or LLLT treatment within the past 1 month or during study period in addition to those provided in the study\n* Contact lens wear in the past 2 weeks or during study period\n* Other active ocular surface diseases or history of ocular surgery or corneal infections the past 6 months",{"count":53,"type":20},[55],"The use of photobiomodulation or low-level light therapy (LLLT) in the ophthalmic field stemmed from dermatology which has shown impact on skin blood flow and regeneration. There has been a rise in clinical interest with emerging evidence in the benefits of photobiomodulation in managing chronic inflammatory conditions such as dry eye disease including improvements in ocular discomfort symptoms, tear film stability and tear volume. Despite the observed clinical benefits, limited research has been done to compare photobiomodulation utilising different wavelengths, as most research on dry eye disease has focused on red wavelengths. It has been purported that blue wavelengths may disrupt microbial growth while red wavelengths stimulate energy production and hence increase heat in the affected tissues, although research into these differential impacts at the ocular surface and external eye has been limited. Hence, the aim of this exploratory clinical trial is to compare the impact of using LLLT incorporating red versus blue wavelengths on eyelid haemodynamics and microbiome, as well as conventional ocular surface measures of patients with dry eye disease and blepharitis (inflammation of the eyelids).\n\nParticipants with dry eye disease, oil gland disruption and blepharitis will receive 3 treatments with these LLLT, each separted by 1 week apart, and followed up to 1 month after the final treatment session. Participants will be randomised to either of 3 groups: Red light only group, Red + Blue light group, or a sham treatment group.",[80,81,82],"Dry Eye Syndromes","Meibomian Gland Dysfunction","Blepharitis",[84],"Low-level light therapy","2026-01-19",{"date":87,"type":34},"2026-01-21",{"date":89,"type":34},"2024-05-01",{"date":38,"type":20},{"name":40,"class":41},2,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":115,"locationsCount":42},"100528685","protecting-the-eyes-of-gamers-with-lubricating-eyedrops-100528685","NCT06163989","Protecting the Eyes of Gamers With Lubricating Eyedrops","The Protective Impact of TheaLoz Duo Eyedrop on the Ocular Surface in Hand-Held Console and Computer Game Users","PROTEGE","Inclusion criteria:\n\n* Individuals with dryness symptoms as assessed with the Ocular Surface Disease Index (OSDI score ≥ 13).\n* Individuals who play handheld console and computer-based games ≥ 2 hours everyday on average\n* Individuals who are comfortable and competent at using smartphone applications\n* Age ≥ 18 years, male or female\n* Able to provide written consent in English\n* Able to instil the treatment lubricating eyedrop on their own, and return any provided eyedrop bottle to the researcher used at the end of the treatment\n* Able to attend multiple visits (3 visits over 2 months)\n\nExclusion criteria:\n\n* Pregnancy\n* Use of any topical ocular medical eyedrops or lubricants in the 1 week prior to starting the study or during the study period. Those who are using existing lubricating eyedrops and are interested in participating will be required to stop their lubricating eyedrops for 1 week prior to commencing the study\n* History of ocular surgery, trauma or infections in the past 6 months",{"count":102,"type":20},28,[55],"The excessive use of screens particularly amongst digital gamers can adversely impact the health of the surface of the eyes with symptoms and signs of surface damage. While strategies including limiting screen time exist, these may be ineffective given the widespread rise of digital device use and gaming culture in the modern era. There is limited evidence for the protective effect of lubricating eyedrops on the ocular surface for handheld console and computer gamers.\n\nThe aim of this study is to investigate the protective effect of a lubricating eyedrop (TheaLoz Duo) on the surface of the eyes in handheld console and computer gamers. The main question it aims to answer is whether TheaLoz Duo could protect the surface of the eyes from dessication and alleviate symptoms of dry eye disease in handheld console and computer gamers.\n\nParticipants will receive either the lubricating eyedrop first for 1 month, followed by a control condition (no eyedrops) for another month, or the other way round. Participants will attend 3 visits in total, each separated by 1 month apart. During each visit, routine clinical assessments of the front of the eye will be conducted. Subsequent findings from this timely study will help improve care of the surface of the eyes for a growing population of gamers worldwide.",[80,106],"Computer Vision Syndrome",[108,109,110],"Lubricating eyedrop","Artificial tears","Ocular surface",{"date":87,"type":34},{"date":113,"type":34},"2024-09-01",{"date":38,"type":20},{"name":40,"class":41},""]